Ascrinvacumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | activin receptor-like kinase 1 |
| Clinical data | |
| Other names | PF-03446962 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6396H9850N1694O2012S44 |
| Molar mass | 144079.64 g·mol−1 |
Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.[1]
This drug was developed by Pfizer Inc.
References
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Bone |
| ||||||||
| Musculoskeletal |
| ||||||||
| Circulatory |
| ||||||||
| Neurologic |
| ||||||||
| Angiogenesis inhibitor |
| ||||||||
| Growth factor |
| ||||||||
| |||||||||
TGFβ receptor superfamily modulators | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type I |
| ||||||||||||||
| Type II |
| ||||||||||||||
| Type III |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.